Your Merchant Center account is suspended. The reason reads something like “healthcare and medicines” or “unapproved pharmaceuticals and supplements,” and your free listings and Shopping ads went dark at the same moment. If you sell dietary supplements or research-use-only peptides, this is the single most common way a Google account dies, and it’s rarely caused by the thing the notice appears to name.
This page gives you three things: a precise breakdown of which policies actually sit behind that “health products” label, a diagnostic you can run in about ten minutes to work out which one is yours, and the specific fix for each. It’s written for operators in the middle of a suspension, not for people planning one. When you’re ready for the broader strategic version, our peptide compliance guide covers catalog structure and site architecture before enforcement happens.
What the “health products” flag actually means
There is no single Google policy called “health products.” The phrase is shorthand that support agents and automated notices use for a cluster of separate policies enforced on separate surfaces by separate systems. Fixing the wrong one is the reason most operators burn three appeals before they get anywhere.
Merchant Center healthcare and medicines policy
The Merchant Center healthcare and medicines policy governs product listings: Shopping ads and free product listings that originate from your feed. It treats healthcare as restricted content, meaning some of it is allowed with conditions and some of it is not allowed anywhere. Its restricted categories include over-the-counter medication, prescription drugs, unapproved pharmaceuticals and supplements, and pregnancy and fertility products. Requirements vary widely by target country: dietary supplements are prohibited outright in some markets, and online pharmacies in most countries need both a third-party accreditation such as LegitScript or NABP and a Google certification.
Nested inside this policy is the piece that catches most supplement sellers. The unapproved pharmaceuticals and supplements list names specific products and ingredients that cannot be promoted anywhere, regardless of country. It explicitly covers products containing ephedra, hCG marketed for weight loss, prohormones and designer steroid compounds, and products whose names are confusingly similar to prohibited substances. Google states plainly that the list is a set of examples, not an exhaustive inventory. That single sentence is why two brands selling the same ingredient can get different outcomes.
One point of precision that matters a great deal for peptide sellers: the word peptide does not appear in either of those two policy documents. Google has not published a peptide-specific rule. Enforcement against research-use-only peptide catalogs runs entirely through catch-all provisions — the non-exhaustive nature of the prohibited list, the confusingly similar names clause, the general prohibition on products marketed as treating disease without approval, and misrepresentation. Anyone who tells you Google bans peptides by name is describing a document that does not exist. That is not good news, because a catch-all is harder to comply with than a list.
Google Ads healthcare and medicines policy
The Google Ads healthcare and medicines policy is a different document governing a different surface: the ads you run from your Google Ads account across Search, Display, Demand Gen, and YouTube. It prohibits promoting anything on the non-exhaustive list of unapproved pharmaceuticals and supplements, products containing ephedra, herbal and dietary supplements with active pharmaceutical or dangerous ingredients, and products marketed to treat disease without the relevant government approval. It also prohibits speculative and experimental medical treatments, and it requires Google certification for pharmacies, telemedicine providers, and pharmaceutical manufacturers. The Ads-side unapproved pharmaceuticals and supplements list carries the same explicit caveat that it provides examples rather than an exhaustive inventory.
The surfaces overlap but the enforcement does not. A Merchant Center suspension kills your free listings and Shopping inventory. A Google Ads suspension kills your text and video campaigns. You can be suspended in one and clean in the other, and the appeals go through different queues. Since 2024, Google has also documented a linked account suspension status, where a suspended Ads account linked to your Merchant Center must be resolved before the Merchant Center issue clears.
Misrepresentation
Misrepresentation is not a health policy at all. It is a prohibited practice, and it exists in parallel versions for Merchant Center and Google Ads. It covers unacceptable business practices, misleading or unrealistic offers, omission of relevant information such as costs, return and refund terms, and unavailable offers. The Ads version breaks out a specific unreliable claims subsection that prohibits improbable results, cure-all framing, unrealistic weight-loss promises, and testimonials implying typical outcomes without disclaimers.
Two things make misrepresentation the most dangerous policy on this list. First, Google classifies violations as egregious and suspends on detection without prior warning. Second, the notice you receive says “misrepresentation” while the actual trigger is usually a health claim, which is why operators mistake it for a healthcare problem and appeal the wrong thing. Google published a clarification of the misrepresentation policy for Shopping ads and free listings in October 2025, adding examples around non-delivery and inoperable return and refund processes. If your suspension names misrepresentation, start with our dedicated fix for peptide misrepresentation suspensions.
Editorial and professional requirements
The fourth policy in the cluster is the least glamorous and the easiest to fix. Editorial and professional requirements govern the site itself: contact information, a checkout every customer can complete, working links, no placeholder text or template images, and return, refund, and cancellation terms that are complete and easy to find. When these fail, the account issue commonly surfaces with wording about your store needing improvement, and Google’s remediation guidance sits on its page covering how to check that your online store is fully functional. It is frequently misread as a health flag because it lands on a health site. We break that one down separately in our guide to website needs improvement suspensions.
Why supplement and peptide sellers trigger this when other verticals do not
A furniture brand with a broken return policy usually gets a warning. A peptide brand with the same defect often gets suspended. The asymmetry is structural, and understanding it changes how you write everything on your site.
Classification is automatic and greedy. Google routes products into the healthcare classifier based on feed attributes and landing page content. Anything that reads as ingestible, bioactive, or physiologically active gets routed there, whether or not you intended a health positioning. Once inside that classifier, the standard of review is far stricter and the tolerance for ambiguity is far lower.
The prohibited list is a template, not a lookup table. Because Google states the unapproved substances list is illustrative, reviewers extend it by analogy. The policy names compound families adjacent to what many peptide and sports-nutrition catalogs carry, and it explicitly targets names confusingly similar to banned substances. A novel compound with no entry on the list is not automatically safe; it is unreviewed. Absence from the list is not permission.
Review is site-wide, not item-level. Reviewers open your homepage, your product pages, your blog, your FAQ, and your policy pages. A single legacy blog post about dosing protocols, or one testimonial page you forgot existed, is enough to reclassify an entire research-use-only catalog as something intended for human consumption. This is the most common failure mode we see, and it is almost always caused by content the operator did not remember publishing.
Supplement copy is naturally claim-dense. The vocabulary that sells supplements — supports, boosts, restores, optimizes, clinically proven — sits directly on the boundary that unreliable claims polices. Before-and-after imagery, percentage results, and outcome-specific testimonials each carry independent risk.
Country targeting multiplies everything. The Merchant Center healthcare policy sets requirements country by country. A catalog that is perfectly compliant for United States targeting can violate policy the moment it is enabled for a market where dietary supplements are prohibited or require specific disclaimers. Our peptide policy map tracks which surfaces and geographies apply to which product classes.
The most common root causes, in the order we encounter them
What follows is ordered by how often each appears in the suspensions we review. This ordering is a pattern observed in practice, not a Google-published statistic.
1. Human-use signals on a research-use-only catalog
What it looks like in the account: the suspension names healthcare and medicines or unapproved pharmaceuticals and supplements, and product-level disapprovals hit your entire peptide catalog at once rather than a subset. In the account, the pattern is total rather than partial, which is the tell that classification changed at the catalog level.
The cause is on the site, not the feed. Reconstitution instructions framed as user guidance, milligram-per-day protocols, stacking pages, cycle-length content, “how to use” sections, customer testimonials describing personal results, physique imagery, or a forum-style community page. Any of these tells the reviewer the product is intended for human consumption, at which point research-use-only labeling reads as a disclaimer bolted onto a consumer product rather than an accurate description of intended use.
2. Claim language triggering misrepresentation
What it looks like: a misrepresentation suspension arriving without warning, often on an account with no prior issues. Product data itself is usually clean, which is what makes it confusing.
The triggers are outcome guarantees, disease references, comparisons to prescription drugs, quantified results, and testimonials that imply typical outcomes without accompanying disclaimers. Note that the policy also reaches implied claims: an ingredient page describing what a compound “does for” a condition is a claim even without the word cure.
3. An ingredient or product on, or analogous to, the prohibited list
What it looks like: disapprovals concentrated on specific SKUs, with the rest of the catalog serving normally. If it escalates to account level, it is usually because the same ingredient recurs across many listings.
Beyond the named substances, watch for the confusingly similar name rule, weight-loss compounds, hormone-adjacent products, and anything a reviewer could map onto the prohormone and designer steroid examples in the published list.
4. Editorial and site trust failures
What it looks like: a store functionality issue, or misrepresentation citing omission of relevant information. Common causes: no physical business address, a contact page with only a form, return and refund terms buried or absent, a checkout that fails for some customer locations, a required field that blocks purchase, broken links, template placeholders, or an under-construction page.
5. Country targeting mismatch
What it looks like: the same product approved in one target country and disapproved in another, or a suspension that appears shortly after you expanded feed targeting. Several markets prohibit dietary supplement promotion entirely or require specific local disclaimers.
6. Certification-gated categories sold without certification
What it looks like: disapprovals referencing pharmacy or healthcare certification. This hits when the catalog includes over-the-counter medication outside the United States, prescription or behind-the-counter products, or anything that positions the store as a pharmacy or telemedicine provider.
7. Linked or duplicate account contamination
What it looks like: a suspension you cannot explain from your own site, sometimes surfacing as linked account suspension or an abuse-of-network reference. Causes include a suspended Google Ads account linked to the Merchant Center, a second Merchant Center account on a related domain, or a prior brand under the same business identity.
The 10-minute diagnostic
Work this in order. Do not skip to the fix; the whole point is to avoid appealing the wrong policy.
Minute 0 to 2: read the exact issue string
Open Merchant Center and go to the account issues or diagnostics view. Copy the exact wording, including the sub-issue. “Misrepresentation” and “Healthcare and medicines” send you down completely different paths. Then check your Google Ads account separately. If both are suspended, resolve the Ads suspension first when the Merchant Center notice references a linked account.
Minute 2 to 4: determine the blast radius
| What you see | Most likely root cause |
|---|---|
| Entire peptide or supplement catalog disapproved at once | Site-level classification change — human-use signals or claims |
| Specific SKUs disapproved, rest serving | Ingredient on or analogous to the prohibited list |
| Account suspended, no product-level issues logged | Misrepresentation or editorial requirements |
| Disapprovals in some target countries only | Country targeting mismatch |
| Suspension with no site change and no feed change | Linked or duplicate account, or a policy update applied retroactively |
Minute 4 to 7: run the reviewer’s path on your own site
Open your site in a private window with no session and no cookies, as a first-time visitor would. In order: homepage, one product page, the checkout as far as the payment step, the contact page, the returns page, and then use site search or your sitemap to find every page containing the words dose, dosage, protocol, mg, cycle, results, before, and testimonial. Reviewers find these pages. So should you, first.
Minute 7 to 10: classify into one of the seven causes
Ask three questions in sequence. First: does anything on the site suggest a research-use-only product is intended for human consumption? If yes, that is your primary cause regardless of what the notice says. Second: does any page promise a health outcome, name a disease, or show a personal result? If yes, misrepresentation is in play. Third: could a stranger find your business address, complete a purchase, and read your return terms in under sixty seconds? If no, editorial requirements are in play. Most suspensions have two causes, not one. Fix both. Our Merchant Center suspension diagnostic hub maps every issue string to its underlying policy if yours does not match the table above.
The fix for each root cause
Fix 1: remove human-use signals from a research-use-only catalog
The standard is consistency, not disclaimers. A research-use-only footer on a page that explains how to take the product does not resolve the contradiction; it documents it. Remove or rewrite every page that frames the product as something a person uses: dosing guidance, administration instructions written in the second person, protocol and stacking content, cycle content, physique imagery, and any testimonial describing a personal outcome. Product titles and descriptions should describe the compound, purity, quantity, and form. Purity documentation, certificates of analysis, storage and handling specifications, and laboratory-appropriate packaging all reinforce the correct classification. Restrict sales language to qualified research contexts, and make sure your terms of sale say the same thing your product pages say. Work through our research peptide compliance checklist line by line before you appeal.
Fix 2: rewrite claim language
Strip outcome guarantees, disease names used as targets, prescription-drug comparisons, and quantified results. Where you keep testimonials, add the disclaimers the unreliable claims policy requires: results are not guaranteed and vary. Replace claim-led headlines with product-led ones. This is unglamorous editorial work and it is the highest-yield hour you will spend. Our guide to getting supplements approved in Merchant Center includes the phrasing patterns that survive review.
Fix 3: remove or segment prohibited ingredients
Remove the affected SKUs from the feed entirely rather than editing titles to obscure them. Renaming a product to something less recognizable is itself a violation under the confusingly similar names rule. If the product is legitimate but ambiguous, you may keep it on the site while excluding it from the feed, provided the site as a whole remains compliant.
Fix 4: repair site trust elements
Publish a physical business address, a monitored email address, and a phone number where practical. Make return, refund, and cancellation terms complete and reachable within one click from any product page. Test checkout end to end from at least two locations and two devices. Remove every placeholder image, Lorem Ipsum block, and dead link. Confirm no page in the purchase path requires an account or presents an interstitial.
Fix 5: correct country targeting
Reduce feed targeting to countries where your product class is permitted, verify each market’s requirements in the healthcare policy country table, and re-expand only after reinstatement.
Fix 6: certification
If the catalog genuinely includes certification-gated products, either apply through Google’s healthcare or online pharmacy application and any required third-party accreditation, or remove those products. There is no third path.
Fix 7: clean up account relationships
Close duplicate Merchant Center accounts, unlink suspended Ads accounts, and resolve the upstream suspension before requesting a Merchant Center review.
The appeal
Request the review from Merchant Center’s diagnostics or the review-and-fix prompt on the home page. Google documents that review requests typically take three to seven business days, and that you have a limited number of attempts before a cooldown is applied, with each unsuccessful re-review potentially extending it. Website-level fixes are sometimes reviewed faster.
Do this before you submit. Complete every fix first. A review request submitted mid-remediation is an appeal you have spent. Take dated screenshots of the changed pages. Wait for your CDN or cache to purge and confirm the live site shows the new version in a private window.
Include: a short statement of which policy you understood to be at issue, a specific list of what changed with URLs, and a one-line statement of how the catalog is positioned. Keep it under 200 words. Reviewers scan.
Leave out: revenue figures, account tenure, mentions of competitors who are still serving, appeals to fairness, threats to move spend, and any argument that the policy is wrong. None of these affect the outcome, and the last one signals you have not made the change.
When the appeal is denied
A denial means the reviewer still sees a violation on the live site. It does not usually mean they saw something new. The most common reasons are that a cached page still served the old copy, that only one of two root causes was fixed, or that a page outside the main navigation still carries the original signal.
Before the next attempt, crawl your own site and check every indexed URL, including blog archives, tag pages, and PDFs. Check any subdomain. Check the pages your theme generates that you never visit. Then wait out the cooldown rather than firing another request immediately, because an additional denial extends it further. If you are two denials deep, stop appealing and change the approach; our guide on what to do after a Merchant Center appeal is denied covers escalation paths, rebuilding on a clean domain, and when a fresh account is legitimate rather than circumvention. Building a new account to evade an active suspension is itself a violation, so the distinction matters.
None of this is legal advice, and it is not a substitute for guidance from counsel on how your products are regulated in the markets you sell into.
If you want a second set of eyes before you spend another appeal, iComChain offers a free 15-minute suspension review. We will run the diagnostic above against your live site and tell you which policy is actually behind your notice. Start with a Merchant Center suspension audit, or book the free call and bring your issue string with you.
Frequently Asked Questions
Why was my Merchant Center account suspended for health products when I only sell research peptides?
Google classifies your products from your feed data and your landing pages, not from your stated intent. If any page on the site describes dosing, administration, personal results, or physique outcomes, reviewers read the catalog as intended for human consumption and apply the healthcare and medicines policy accordingly. Research-use-only labeling only holds when every page on the site is consistent with it. A disclaimer sitting under a dosing guide doesn’t resolve that contradiction, it confirms it. Audit the whole site, old blog posts included, before you appeal.
Does Google have a policy that specifically bans peptides?
No. The word peptide doesn’t appear in the Merchant Center healthcare and medicines policy, and it isn’t on the unapproved pharmaceuticals and supplements list either. Enforcement reaches research-use-only peptide catalogs through general provisions instead. The prohibited list is explicitly non-exhaustive. Names confusingly similar to banned substances are covered. Products marketed as treating disease without approval are prohibited. Misrepresentation applies to claims. That makes compliance harder rather than easier, because there’s no list you can check yourself against.
How long does a Merchant Center suspension appeal take?
Google states that review requests typically take three to seven business days, and site-level issues are sometimes reviewed faster than that. What you can’t control is the number of attempts you get. After unsuccessful reviews Google applies a cooldown during which the review button is disabled, and each further denial can extend it. So treat every appeal as scarce. Complete all your remediation, confirm the live site actually reflects it, and only then submit.
Is my suspension a healthcare policy issue or a misrepresentation issue?
Read the exact issue string inside Merchant Center rather than the email subject line. Healthcare and medicines issues usually come with product-level disapprovals you can see in diagnostics. Misrepresentation typically shows up as an account-level suspension with no product issues logged at all, because it’s enforced as an egregious violation without prior warning. If your notice says misrepresentation, the trigger is almost always claim language, missing return or contact information, or a checkout defect. It’s rarely the products themselves.
Can I sell dietary supplements on Google Shopping at all?
Yes, in permitted markets and within the healthcare policy’s limits. In the United States, ordinary retailers can list supplements without certification. What’s prohibited everywhere is anything on Google’s unapproved pharmaceuticals and supplements list, products containing ephedra, supplements with active pharmaceutical or dangerous ingredients, and products marketed as treating disease without the relevant approval. Watch the geography too. Several countries prohibit supplement promotion entirely or require local disclaimers, so verify each target country before you expand feed targeting.
Does fixing my product feed resolve a health products suspension?
Usually not. Feed edits resolve item-level data problems, such as a prohibited ingredient sitting in a product title. Account-level health suspensions are almost always driven by landing page and site content, and the feed can’t change either of those. Here is the tell: if your entire catalog was disapproved simultaneously, the cause is classification at the site level, and no amount of feed work will move it. Fix the site first. Then confirm the feed matches what the site now says.
My Google Ads account is fine but Merchant Center is suspended. Why?
Because they’re separate accounts, governed by separate policy documents and reviewed by separate systems. The Merchant Center healthcare and medicines policy applies to Shopping ads and free listings. The Google Ads healthcare and medicines policy applies to Search, Display, Demand Gen, and YouTube campaigns. One can be enforced without the other. The exception runs the other way: when an Ads account linked to your Merchant Center is suspended, Google may surface a linked account suspension that you must resolve upstream first.
Sources
Every policy and regulatory claim in this article is drawn from the primary documents below, checked on 15 August 2026. Platform policies change without notice; verify against the current version before acting.
- Merchant Center healthcare and medicines policy — Google
- unapproved pharmaceuticals and supplements — Google
- Google Ads healthcare and medicines policy — Google
- unapproved pharmaceuticals and supplements list — Google
- Merchant Center — Google
- Google Ads — Google
- unreliable claims — Google
- misrepresentation policy for Shopping ads and free listings — Google
- Editorial and professional requirements — Google
- how to check that your online store is fully functional — Google